Amgen To Present Lumakras Combination Data From Phase 1b Study On KRAS G12C-mutated Cancers

THOUSAND OAKS (dpa-AFX) - Amgen (AMGN) announced new combination study results from the Phase 1b CodeBreaK 101 study, a comprehensive global master protocol trial evaluating the safety and efficacy

Related Keywords

,Virtual International Conference On Molecular ,Drugging Difficult Target ,International Conference ,Molecular Targets ,Cancer Therapeutics ,Amgen ,Present ,Lumakras ,Combination ,Data ,Rom ,Hase ,Study ,Ras ,12c ,Mutated ,Cancers ,